| 0.256 -0.014 (-5.08%) | 04-19 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.2 | 1-year : | 1.34 |
| Resists | First : | 1.02 | Second : | 1.14 |
| Pivot price | 0.92 |
|||
| Supports | First : | 0.82 | Second : | 0.69 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.92 |
| MA(100) : | 1.41 |
MA(250) : | 1.45 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26 |
D(3) : | 28 |
| RSI | RSI(14): 36.2 |
|||
| 52-week | High : | 2.2 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PBIO ] has closed above bottom band by 16.4%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.92 | 0.92 - 0.92 |
| Low: | 0.82 - 0.83 | 0.83 - 0.83 |
| Close: | 0.86 - 0.87 | 0.87 - 0.88 |
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.
Wed, 17 Apr 2024
StockNewsNow.com Publishes SNNLive Video Interview Q1 2016 Update With Pressure Biosciences, Inc. - Yahoo Movies UK
Tue, 02 Apr 2024
Pressure BioSciences' Uncle Bud's Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive ... - Markets Insider
Mon, 26 Feb 2024
Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure ... - Yahoo Finance
Thu, 15 Feb 2024
Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded ... - GlobeNewswire
Mon, 05 Feb 2024
Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear ... - Yahoo Finance
Thu, 01 Feb 2024
Pressure BioSciences Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 12 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | -0.29 |
| EPS Est Next Year | -0.16 |
| Book Value (p.s.) | -2.4 |
| Profit Margin | 0 % |
| Operating Margin | -283.3 % |
| Return on Assets (ttm) | -126.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 92.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | 0 |
| Price to Book value | -0.37 |
| Price to Sales | 6.15 |
| Price to Cash Flow | -2.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2017-06-04 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|